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Abstract. The microphthalmia with linear skin defects syn-
drome (MLS) is an X-linked dominant disorder with male
lethality. In the majority of the patients reported, the MLS syn-
drome is caused by segmental monosomy of the Xp22.3 region.
To date, five male patients with MLS and 46,XX karyotype
(“XX males”) have been described. Here we report on the first
male case with MLS and an XY complement. The patient
showed agenesis of the corpus callosum, histiocytoid cardio-
myopathy, and lactic acidosis but no microphthalmia, and car-
ried a mosaic subtle inversion of the short arm of the X chro-
mosome in 15% of his peripheral blood lymphocytes,
46,Y,inv(X)(p22.13F22.2p22.32F22.33)[49]/46,XY[271].
By fluorescence in situ hybridization (FISH), we showed that
YAC 225H10 spans the breakpoint in Xp22.3. End-sequencing
and database analysis revealed a YAC insert of at least 416 kb
containing the genes HCCS and AMELX, and exons 2–16 of
ARHGAP6. Molecular cytogenetic data suggest that the
Xp22.3 inversion breakpoint is located in intron 1 of ARH-
GAP6, the gene encoding the Rho GTPase activating protein 6.
Future molecular studies in karyotypically normal female MLS
patients to detect submicroscopic rearrangements including the
ARHGAP6 gene as well as mutation screening of ARHGAP6
in patients with no obvious chromosomal rearrangements will
clarify the role of this gene in MLS syndrome. 
Copyright © 2002 S. Karger AG, Basel
The microphthalmia with linear skin defects syndrome
(MLS; MIM 309801) is a severe developmental disorder. Ma-
jor clinical signs are localized dermal aplasia and microphthal-
mia. Occasional abnormalities include agenesis of the corpus
callosum, sclerocornea, chorioretinal abnormalities, infantile
seizures, congenital heart defect, and mental retardation. At
least 30 patients have been described so far (Friedman et al.,
1988; Al-Gazali et al., 1990; Donnenfeld et al., 1990; Temple et
al., 1990; Allanson and Richter, 1991; Gericke et al., 1991;
Thies et al., 1991; Lindor et al., 1992; Naritomi et al., 1992;
Happle et al., 1993; Bird et al., 1994; Eng et al., 1994; Lindsay
et al., 1994; McLeod et al., 1994; Mücke et al., 1995; Camacho
et al., 1997; Paulger et al., 1997; Cox et al., 1998; Ogata et al.,
1998; Stratton et al., 1998; Zvulunov et al., 1998; Kono et al.,
1999; Kayserili et al., 2001; Anguiano et al., 2003). 
The MLS syndrome is considered to be an X-linked domi-
nant male lethal disorder. Conventional and molecular cyto-
genetic studies of most MLS patients revealed an XX comple-
ment with a variety of X-chromosomal aberrations, including
deletion of Xpter→p22 or unbalanced translocation between
the X chromosome and an autosome or the Y chromosome,
that all resulted in segmental monosomy of Xp22.3. Remark-
ably, four female patients with an apparently normal karyotype
have also been described (Happle et al., 1993; Bird et al., 1994;
Cox et al., 1998; Zvulunov et al., 1998) suggesting that submi-
croscopic rearrangements or “short length” mutations in a yet
unidentified gene may also be responsible for the trait. To date,
three affected males and twin brothers have been reported, all
with an XX complement and a translocation between Xp and
Yp (Lindsay et al., 1994; Paulger et al., 1997; Stratton et al.,
1998; Kono et al., 1999; Anguiano et al., 2003). A sixth patient
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had ambiguous genitalia and a 46,XX karyotype (Camacho et
al., 1997). 
By mapping the breakpoints of MLS patients, an F570-kb
minimal region of monosomy has been identified in Xp22.3
(Wapenaar et al., 1993; 1994), distal to AMELX (amelogenin)
(Lagerstrom et al., 1991), and cloned into overlapping cosmids
(Cox et al., 1998). Three genes have been mapped and charac-
terized in the critical deletion interval for MLS: MID1 (mid-
line-1) mutated in the X-linked Opitz G/BBB syndrome (Qua-
deri et al., 1997), HCCS which encodes the human holo-
cytochrome c-type synthetase (Schaefer et al., 1996), and ARH-
GAP6 encoding a Rho GTPase activating protein (Schaefer et
al., 1997). Mice deficient for the Rho GAP domain of Arhgap6
did not show any detectable phenotypic or behavioural abnor-
malities (Prakash et al., 2000). In marked contrast, deletion of
the Hccs gene in the mouse leads to lethality of the embryos
early in development suggesting that loss of HCCS causes the
male lethality of MLS syndrome (Prakash et al., 2002). 
Another important factor in determining the MLS pheno-
type seems to be the pattern of X inactivation. It has been pro-
posed that functional absence of the MLS gene caused by inac-
tivation of the normal X chromosome in patients with Xp22
monosomy may play a critical role in the development of MLS
(reviewed in Van den Veyver, 2001). Moreover, variable tissue-
specific X-inactivation is likely to account both for the intra-
familial variability and clinical divergence in sporadic cases
(Allanson and Richter, 1991; Ballabio and Andria, 1992;
Mücke et al., 1995). 
In this report, we describe the first case of MLS syndrome in
a male with an XY complement and a mosaic paracentric
inversion of the short arm of the X chromosome in blood lym-
phocytes.
Materials and methods
Case report
The male infant was born to non-consanguineous parents by Cesarean
section the 36th week of gestation. Ultrasound examination revealed intra-
uterine growth retardation. There was no history of prenatal drug exposure or
intrauterine infection. At birth, the patient was noted to have bilateral para-
nasal linear skin defects but no microphthalmia. Birth weight was low
(1,620 g, –3 SD) and a severe postnatal metabolic acidosis developed. Ultra-
sound investigations revealed lissencephaly and agenesis of the corpus callo-
sum as well as pericardial effusion and mild hypertrophic cardiomyopathy.
Blood pyruvate concentration was normal with markedly elevated blood (6–
18 mmol/l, normal !2) and CSF lactate values (10.7 mmol/l, normal !1.5),
and a slightly elevated alanine level (8.5 mg/dl, normal !5.1). Lactic aciduria
and ketonuria were present. Respiratory chain enzyme activities were in the
normal range both in a muscle biopsy and in skin fibroblasts. The patient was
treated symptomatically with bicarbonate buffer, a specific vitamin cocktail
(containing carnitine, coenzyme Q, riboflavin, vitamin K1, and thiamine),
and ketogenic diet without any obvious benefit. During follow-up studies, he
showed failure to thrive, cardiomyopathy with supraventricular tachycardia
and pericardial effusion, hepatic failure with cholestatic hepatopathy, and a
deteriorating lactic acidosis. He died from multiple organ failures at the age
of four months. Postmortem autopsy confirmed the agenesis of the corpus
callosum and the severe liver disease with fatty degeneration and fibrosis.
Histologic investigation of the heart showed histiocytoid/oncocytic cardio-
myopathy and subendocardial myocardial necrosis.
Conventional cytogenetic and FISH studies
Chromosome preparations were made from PHA-stimulated peripheral
blood lymphocytes. Cytogenetic analysis was carried out by an improved
high-resolution RBG-H banding method (700–1,000 band level) (Werner
and Spiegler, 1988). Fluorescence in situ hybridization was performed as pre-
viously described (Bartsch et al., 1999). DOP-PCR products of YAC 225H10
were labeled using tetramethylrhodamin-6-dUTP. Chromosomes were coun-
terstained using DAPI (Roche) and mounted in antifading solution (Vector
Labs). Slides were analyzed by AxiophotTM epifluorescence microscopes
(Zeiss) and the ISISTM digital imaging system (Meta Systems). 
Derivation of YAC end-sequences
End-sequences of YAC clone 225H10 were obtained as described by
Nehls et al. (1995). Briefly, total yeast DNA was isolated by standard proto-
cols and digested with Sau3AI, HpaII, TaqI, HinPI, AluI, BstUI, HaeIII,
RsaI, and NlaIII. DNA fragments were ligated to one of two vectorette “iso-
forms” and subsequently, end sequences were amplified selectively in prima-
ry and secondary PCR reactions. Purified amplicons (JETQUICK PCR puri-
fication kit, Genomed) were directly sequenced using the ABI Prism Dye
Terminator Kit (PE Applied Biosystems) and the ABI Prism 377 automatic
sequencer (PE Applied Biosystems).
Results
Conventional and molecular cytogenetic studies
Cytogenetic investigation of peripheral blood lymphocytes
by high resolution RBG-H banding revealed two cell lines, one
with an apparently normal (46,XY) karyotype and a second one
with an aberrant karyotype. The normal karyotype was ob-
served in 271 (F85%) of the 320 metaphases analyzed (Fig. 1a,
b). In 49 metaphases, an aberrant R-banding pattern was found
at the telomeric part of the short arm of the X chromosome
(Fig. 1a, c). A terminal or an interstitial deletion was unlikely
for both the normal and rearranged X chromosomes had the
same length. Fluorescence in situ hybridization (FISH) analysis
with cosmid 34F5, containing exons 1–5 of the SHOX gene
located in the pseudoautosomal region (PAR), and with cosmid
2.1, that maps about 1,700 kb proximal to SHOX, yielded a
single signal on the terminal end of the X chromosome in all
metaphases analyzed (data not shown). Taking the cytogenetic
and FISH data together, the rearrangement observed was inter-
preted as a paracentric inversion with the distal breakpoint in
Xp22.32Fp22.33 and the proximal breakpoint in Xp22.13F
p22.2, karyotype mos 46,Y,inv(X)(p22.13F22.2p22.32F
22.33)/46,XY. 
To map the putative inversion breakpoint in Xp22.3 more
precisely, we performed FISH analysis with YAC clone
225H10, which contains part of the previously defined MLS
critical region (Wapenaar et al., 1993) and which has been
found to be deleted in three patients with MLS syndrome
(Lindsay et al., 1994). In the majority of the 38 metaphases
analyzed with YAC 225H10, we observed one distinct signal on
the short arm of the X chromosome (Fig. 2a). However, in three
metaphases, this YAC produced two signals of similar intensity
(Fig. 2b), one in Xp22.3 and another one located more proxi-
mally, suggesting that this clone is bridging the breakpoint. 
YAC 225H10 contains exons 2–16 of the ARHGAP6 gene
in Xp22.3
By using vectorette PCR, we determined the end-sequences
of YAC 225H10 and initiated BLASTN database searches at
the NCBI. YAC endmarker A was located at position 11,514 bp
in BAC clone GS-602M16 (GenBank acc. no. AC003657) and
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Fig. 1. Mosaic paracentric inversion of
the short arm of the X chromosome
[inv(X)(p22.13F22.2p22.32F22.33] in the
patient with MLS syndrome. (a) Ideogram of a
high resolution RBG-banded X chromosome.
The upper arrow indicates the breakpoint in
Xp22.33Fp22.32, whereas the lower one
points to that in Xp22.2Fp22.13. (b) Three
RBG-H-banded normal X chromosomes and
(c) three rearranged X chromosomes of the
patient. The two short lines point to the cen-
tromere and the arrow in (c) marks the in-
verted region.
Fig. 2. Characterization of the inversion breakpoint in Xp22.3.
(a, b) Fluorescence in situ hybridization with YAC clone 225H10 on meta-
phase spreads of the patient. (a) In the majority of the metaphases analyzed,
YAC 225H10 gives one signal on the X chromosome. (b) In contrast, YAC
225H10 produces two signals in a small number of metaphases with the rear-
ranged X chromosome of the patient. The probe is labeled by tetramethyl-
rhodamin (depicted in green). Chromosomes are counterstained with DAPI
(depicted in red). (c) Schematic representation of the critical breakpoint area
in Xp22.3. The uppermost arrow indicates the proximal part of the critical
region of the MLS syndrome. The second line represents a region in Xp22.3
in telomere (Xpter) to centromere (cen) orientation, that is not drawn to
scale. Microsatellite marker loci and the deletion breakpoint of MLS patient
BA325 (zigzag line), that defines the proximal boundary of the MLS critical
region, are shown. Middle lines indicate genomic contig sequences and PAC,
BAC, or cosmid clones that are completely sequenced. The bottom line
represents the insert of YAC 225H10. Below the YAC insert, exons of the
genes ARHGAP6, HCCS, and AMELX are shown by thin vertical bars
which are partially numbered. White boxes indicate untranslated regions of
the ARHGAP6 gene. The bracket at the very bottom shows the putative
breakpoint region in the patient.
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at position 4,255,725 bp in human genome contig
NT_011812.10 (Fig. 2c). We mapped YAC endmarker B to
position 29,485 bp in clone GSHB-590J6 (GenBank acc. no.
AC004554) and to position 4,821,848 bp in contig
NT_011812.10 (Fig. 2c). Thus, an insert size of 566,123 bp was
determined for YAC 225H10 that agreed well with the size of
560 kb estimated previously by PFGE analysis (Ferrero et al.,
1995). By compiling recent data, we found three genes, HCCS,
AMELX, and ARHGAP6, present on YAC 225H10, which
contains the putative inversion breakpoint of the patient’s rear-
rangement in Xp22.3 (Fig. 2c). 
ARHGAP6 consists of 16 exons and spans a region of
528 kb. With the exception of exon 1, that is located 373 kb
centromeric to the previously designated first exon (currently
exon 2), all exons of the ARHGAP6 gene are present on the
insert of YAC 225H10. The fact that exon 1 of ARHGAP6 is
not covered by the YAC bridging the putative breakpoint sug-
gests that the ARHGAP6 gene is disrupted by the inversion in
Xp22.3 in F15% of the patient’s lymphocytes. Moreover, the
equal intensities of the split signals obtained by FISH (Fig. 2b)
suggest that the breakpoint is located approximately in the mid-
dle of the insert, i.e. in intron 1 of ARHGAP6 (Fig. 2c). 
In an attempt to further characterize the breakpoint, we per-
formed 3) RACE experiments on cDNA prepared from fibro-
blast RNA of the patient using a “forward” primer located in
exon 1 of ARHGAP6 in combination with a polyT primer.
Although we did several rounds of RACE-PCR, cloned the
PCR products, and sequenced the inserts of about 70 clones, we
failed to identify any aberrant ARHGAP6 transcript consisting
of the first exon of ARHGAP6 fused to a sequence originating
from the proximal inversion breakpoint in Xp22.13Fp22.2
(data not shown). Possibly, the presence of the chromosomal
inversion in only a distinct portion of the patient’s cells has
significantly hampered the identification of such aberrant fu-
sion transcripts. 
Discussion
In the present paper, we describe the first 46,XY male with
MLS syndrome, who carries a mosaic of a paracentric inversion
of Xp with one breakpoint in Xp22.32Fp22.33 and the other
one in Xp22.13Fp22.2 in peripheral blood lymphocytes. In
addition to MLS, he showed histiocytoid cardiomyopathy and
a deteriorating lactic acidosis. To our knowledge, the patient
described here is the first MLS case with an X-chromosomal
rearrangement other than a terminal deletion or translocation
resulting in monosomy of Xp22.3.
We mapped the telomeric inversion breakpoint in
Xp22.32Fp22.33 to a region of F500 kb, most likely in intron
1 of ARHGAP6, i.e. our data suggested that the ARHGAP6
gene was disrupted in a portion of the patient’s lymphocytes.
Several lines of evidence suggest that ARHGAP6 is an attrac-
tive candidate gene for MLS syndrome. First, ARHGAP6 is
expressed in fetal brain and retina (Schaefer et al., 1997). Var-
ious protein isoforms are generated by extensive alternative
splicing (Prakash et al., 2000; Kayserili et al., 2001) including
three that contain amino acids encoded by exon 1 (GenBank
acc. nos. AF012272, AF022212, and AF117067). Expression of
a variant in the tissues affected in MLS syndrome would sug-
gest that this isoform plays a role in the normal development
and/or function of these organs. However no data exist so far on
the tissue-specific expression of these ARHGAP6 transcripts/
isoforms. Second, at least exons 6–16 of ARHGAP6 are deleted
in all MLS patients. The proximal boundary of the MLS critical
region has been located in intron 1 of ARHGAP6 by defining
the deletion breakpoints of the female patient BA325 (Wape-
naar et al., 1994) and of the patient described by Kayserili et al.
(2001), both presenting with characteristic clinical features of
MLS syndrome. In the patient reported here, the mRNAs tran-
scribed from the aberrant X chromosome would not produce
any functional ARHGAP6 variant containing the first 196 ami-
no acids encoded by exon 1. However, other transcripts with
exon 2 as the first exon might be normally expressed from the
rearranged X chromosome. Thus, one can hypothesize that the
absence of an ARHGAP6 isoform containing the amino acids
encoded by exon 1 is the cause of the MLS syndrome in the
patient. Clearly, we can not exclude that another not yet identi-
fied gene present on YAC insert 225H10, possibly located in
the 1373-kb intron 1 of ARHGAP6, is implicated in the patho-
genesis of MLS syndrome. 
The function of ARHGAP6 has been investigated by gener-
ating Arhgap6-deficient mice and in vitro expression studies
(Prakash et al., 2000). The targeted Arhgap6 allele encodes a
putative protein of 470 amino acids that lacks the Rho GAP
domain and the C-terminus. Remarkably, loss of Rho GAP
function did not cause any detectable phenotypic or behaviour-
al abnormalities in the mutant mice. The N-terminus of ARH-
GAP6 has been shown to be required for the regulation of cell
morphology and actin polymerization (Prakash et al., 2000)
and thus, it seems critical for proper ARHGAP6 function. This
again indicates that mutated ARHGAP6 isoforms containing
an N-terminus encoded by exon 1 may be implicated in MLS
syndrome. 
Mutation analysis of ARHGAP6 in MLS patients has not
been performed because this gene was always included in the
terminal Xp22 deletions. Several MLS syndrome patients have
been reported with obviously normal karyotypes (Happle et al.,
1993; Bird et al., 1994; Cox et al., 1998; Zvulunov et al., 1998;
Peter Meinecke, personal communication). However, these pa-
tients may carry chromosomal rearrangements that escaped
detection by routine cytogenetic analysis. Further studies, in-
cluding FISH and Southern blot, will help to elucidate the pres-
ence of small rearrangements in the above mentioned patients.
Finally, mutation screening of ARHGAP6 would be of great
interest in cases with no chromosomal rearrangements. 
In FISH analysis, YAC 225H10 produces split signals on
the short arm of the rearranged X chromosome in three meta-
phases of the patient analyzed suggesting that this YAC spans
the breakpoint in the patient. Nonetheless, alternative interpre-
tations of the results obtained are also possible although not
very likely. A complex rearrangement might have occurred
with a duplication in addition to the inversion. Thus, split sig-
nals may result from a duplication comprising (part of) the
YAC insert at the proximal inversion breakpoint in
Xp22.2Fp22.13. Indeed, characterization of an X/10 translo-
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cation by FISH revealed that, in addition to the translocation, a
duplication of at least 500 kb occurred at the breakpoint region
in 10q24 (I. Martinez-Garay and K. Kutsche, unpublished
data). Low-copy repeats (LCRs) represent a new class of repeti-
tive DNA element that has been recently identified in the
human genome. Intrachromosomal duplications are typically
found on a single chromosome or in a single chromosomal band
(Mazzarella and Schlessinger, 1998; Ji et al., 2000). Two fami-
lies of LCRs, CRI-S232 and G1.3 (DXF22S), also known as
FAM9 gene family, were found to be interspersed on Xp22.3
(Bardoni et al., 1988; Ballabio et al., 1990; Martinez-Garay et
al., 2002). Thus, the presence of a segmental duplication on the
short arm of the X chromosome may also account for the split
signals seen in the patient. 
The patient had bilateral paranasal linear skin defects but
no microphthalmia and thus showed an “incomplete” pheno-
type of MLS syndrome. Certainly, the mosaicism present in our
patient, as in patient 2 described by Lindsay et al. (1994), may
have contributed to the milder phenotype. Four female patients
with MLS but without microphthalmia have also been re-
ported. Cytogenetic analysis revealed a deletion of Xpter→
p22.2 in one patient (Allanson and Richter, 1991), a 45,X/
46,X,del(X)(pter→p22.2) mosaicism in the second one (pa-
tient 2 in Lindsay et al., 1994), and a normal karyotype in the
two remaining cases (patient BA529 in Cox et al., 1998; Zvulu-
nov et al., 1998). Thus, although two patients lacked larger por-
tions of Xp, they did not show the complex phenotype suggest-
ing that the MLS phenotype was not necessarily caused by a
larger deletion. Instead, different patterns of X inactivation
may account for the variability of the phenotype. The finding of
two karyotypically normal patients (Cox et al., 1998; Zvulunov
et al., 1998) suggests that submicroscopic gene defect(s) togeth-
er with a preferentially inactivated normal X chromosome may
also cause the MLS phenotype in females.
The patient presented with severe lactic acidosis, in addi-
tion to MLS syndrome. Defects in the pyruvate dehydrogenase
(PDH) complex are an important cause of primary lactic acido-
sis (Lissens et al., 2000). The great majority of PDH complex
deficiencies result from mutations in the PDHA1 gene (Dahl et
al., 1992; Lissens et al., 2000) which is located in Xp22.2→
p22.1 (Brown et al., 1989). PHDA1 encodes the ·-subunit of
the pyruvate dehydrogenase (E1), one of three components of
the PDH complex. Remarkably, the proximal inversion break-
point of the patient was localized to Xp22.2Fp22.13 suggest-
ing that the PDHA1 gene could be functionally impaired by the
rearrangement. 
Somatic mosaicism is becoming increasingly recognized for
explaining the phenotype of surviving male patients carrying
X-linked dominant mutations, e.g. in incontinentia pigmenti
(IKBKG), Rett syndrome (MECP2), or chondrodysplasia punc-
tata (EBP) (Metzenberg et al., 1999; Clayton-Smith et al., 2000;
Armstrong et al., 2001; Kenwrick, 2001; Topçu et al., 2002). We
assume that the paracentric inversion of the X chromosome
occurred postzygotically in a particular subset of the patient’s
cells. Furthermore, it is likely that the inversion was also present
in a significant portion of cells of skin, brain, and heart for the
patient showed typical features of MLS syndrome, in addition to
a histiocytoid/oncocytic cardiomyopathy. Two female patients
with MLS syndrome and oncocytic cardiomyopathy (Bird et al.,
1994) or hypertrophic cardiomyopathy (Happle et al., 1993)
have been reported showing similarities in physical findings and
clinical course. Both had normal karotype suggesting that the
genetic defect that caused the MLS syndrome might also be
implicated in histiocytoid cardiomyopathy. It is of interest to
note that the gene for holocytochrome c-type synthetase, HCCS,
resides in the critical region for MLS syndrome (Schaefer et al.,
1996). It has been speculated that a defect of the HCCS enzyme
activity could give rise to a nuclear-encoded respiratory chain
defect (Schwarz and Cox, 2002) which, in turn, may lead to (his-
tiocytoid) cardiomyopathy in MLS cases. Remarkably, a mis-
sense mutation in the mitochondrial cytochrome b (MTCYB)
gene was found in a patient with histiocytoid cardiomyopathy
(Andreu et al., 2000) suggesting that a mitochondrial respiratory
chain enzyme is involved in the pathogenesis of (one form of)
this heart phenotype.
To understand the contribution of the genes located in the
critical region for MLS syndrome, and in particular that of
HCCS, mouse models were created with overlapping deletions
similar to the human MLS deletion (Prakash et al., 2002). The
complete loss of Hccs leads to embryonic lethality that can be
rescued by overexpressing the human HCCS gene from a BAC.
These data suggest that male lethality in MLS is caused by defi-
ciency of HCCS (Prakash et al., 2002). The distal inversion
breakpoint of the patient maps at least 170 kb proximal to the
3) end of HCCS suggesting that this gene is not directly
impaired by the chromosomal rearrangement. Although it
seems not likely, we cannot exclude with certainty an involve-
ment of the HCCS gene in the phenotypic features of MLS syn-
drome in the patient. Further studies are required to unravel
the role of HCCS and ARHGAP6 in this syndrome.
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